Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the ...

Amgen (AMGN) stock slipped on Wednesday after the biotechnology company announced plans to create a $600 million hub at its ...

Amgen (AMGN) recently announced plans to invest $600 million for a new science and innovation center at its headquarters, ...

Amgen's share price has dropped by a material amount over the past couple of months. See how recent price drop presents a good opportunity for value investors.

Recent discussions on X about Amgen (AMGN) have centered around the stock's price movements and technical indicators. Many users have noted the stock's recent decline, with some highlighting a ...

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen's Q3 2023 financial performance showed increased total revenues and product sales, driven by volume growth and strong international markets. Click here to read my analysis.

Price targets normally reflect where analysts believe a stock can go over the course of the next 12 months or so; in the long run, Amgen may have even more upside depending on how it manages its ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage ...